

## **CURRICULUM VITAE**

JOHN A. BOSSO, PHARM.D.

### **OFFICE ADDRESS:**

College of Pharmacy  
Medical University of South Carolina  
280 Calhoun St., PO Box 250142  
Room QE223  
Charleston, SC 29425

Telephone (843) 792-8501  
Beeper (843) 792-0590, digital  
beeper #12045  
e-mail: [bossoja@musc.edu](mailto:bossoja@musc.edu)  
FAX (843)792-1617

### **EDUCATION:**

State University of New York at Buffalo, School of Pharmacy  
Bachelor of Science (Pharmacy) 1970; Doctor of Pharmacy 1973

### **BOARD CERTIFICATION:**

Pharmacotherapy, 1991-  
Added Qualifications in Infectious Diseases, 1999-

### **AWARDS AND HONORS:**

New York State Regents Scholarship, 1965-70.  
Rho Chi Society (Pharmacy Honor Society), 1974.  
Lederle Faculty Award, 1975.  
Award for Achievement in the Professional Practice of Hospital Pharmacy (American Society of Hospital Pharmacists, Research and Education Foundation), 1980.  
Fellow, American College of Clinical Pharmacy, 1987.  
American College of Clinical Pharmacy-Merck Sharp & Dohme Infectious Disease Research Fellowship (Preceptor), 1991-2.  
American College of Clinical Pharmacy-Miles Infectious Disease Research Fellowship (Preceptor), 1995-6.  
Phi Lambda Sigma (Pharmacy Leadership Society), 2002.

### **EXPERIENCE - PRACTICAL:**

Clinical Specialist, Medical University of South Carolina Children's Hospital, Charleston, SC, 1992-  
Assistant Director, Clinical Education & Research, Pharmacy Department, Texas Children's Hospital,  
Houston, TX, 1991-2  
Coordinator, Clinical Education & Research, Pharmacy Department, Texas Children's Hospital, Houston,  
TX, 1989-91.  
Clinical Pharmacist, Texas Children's Hospital, Houston, TX, 1989-92.  
Director, Clinical Pharmacology Research Program, Intermountain Cystic Fibrosis Center, Salt Lake City,  
UT, 1986-9.  
Coordinator, Clinical Pharmacy Services, University of Utah Hospital, 1978-82.  
Clinical Pharmacist (Pediatrics), University of Utah Hospital, 1973-89.

### **EXPERIENCE - ACADEMIC:**

**Medical University of South Carolina College of Pharmacy**  
Professor, 1992-

**EXPERIENCE - ACADEMIC (continued):**

**Medical University of South Carolina College of Medicine**

Professor of Pediatrics, 1992-

**Medical University of South Carolina College of Graduate Studies**

Member, Graduate Faculty, 2000-

**University of Houston**

Professor, 1989-92

**Baylor College of Medicine**

Adjunct Associate Professor of Pediatrics, 1989-92

**University of Utah College of Pharmacy**

Professor of Clinical Pharmacy, 1985-9

Associate Professor of Clinical Pharmacy, 1979-85

Assistant Professor of Clinical Pharmacy, 1975-9

Instructor of Clinical Pharmacy, 1973-5

**University of Utah School of Medicine**

Adjunct Professor of Pediatrics, 1987-9

Adjunct Associate Professor of Pediatrics, 1979-87

Adjunct Assistant Professor of Pediatrics, 1977-9

Adjunct Instructor of Pediatrics, 1975-7

**University of California at San Francisco School of Pharmacy**

Visiting Associate Professor of Pharmacy, 1981

**EXPERIENCE - ADMINISTRATIVE:**

Head, Division of Clinical Pharmacy Sciences, Medical University of South Carolina College of Pharmacy, 1997- present

Vice Chair for Research, Department of Hospital Pharmacy Practice & Administration, Medical University of South Carolina College of Pharmacy, 1992-5

Vice Chair, Department of Pharmacy Practice, University of Houston College of Pharmacy, 1990-2

**RESEARCH, SCHOLARSHIP AND OTHER CREATIVE WORK:**

**PUBLICATIONS:**

**CHAPTERS:**

1. Bosso JA, Devenport JK, Hart LL. Psychiatric drug therapy, *in* Self-assessment of current knowledge in clinical pharmacy. 2<sup>nd</sup> Edition. Garden City, NJ, Medical Examination Publishing Co., 1978.
2. Bosso JA, Pediatric Services, *in* The practice of pharmacy, Cincinnati, OH, Harvey Whitney Books, 1982.
3. Mutchie KM, Bosso JA. Congenital biliary atresia, *in* Applied therapeutics: The clinical use of drugs, 3<sup>rd</sup> Edition, San Francisco, CA, Applied Therapeutics, Inc., 1983.
4. Nappi JM, Bosso JA. Utilization of drug levels, *in* Laboratory medicine in clinical practice - an efficient use of the laboratory in patient management, Littleton, MA, Wright-PSG, Inc., 1983.
5. Bosso JA. Deliberations of the Utah institutional review board concerning the artificial heart, *in* After Barney Clark: Reflections of the Utah artificial heart program. Austin, TX, University of Texas Press, 1984.

## CHAPTERS (continued):

6. Bosso JA, Padula SJ, Freston JW. Diseases: Manifestations and pathophysiology, *in* Remington's pharmaceutical sciences, 17<sup>th</sup> Edition, Philadelphia, PA, Mack Publishing Co., 1985.
7. Bosso JA. Cystic fibrosis, *in* DiPiro JT et al, *Pharmacotherapy: A pathophysiologic approach*. Harvard, MA, Elsevier Science Publishing Co., 1988.
8. Bosso JA, Freston JW. Diseases: Manifestations and pathophysiology, *in* Remington's pharmaceutical sciences, 18<sup>th</sup> Edition, Philadelphia, PA, Mack Publishing Co., 1990.
9. Bosso JA. Cystic fibrosis, *in* DiPiro JT et al, eds., *Pharmacotherapy: A pathophysiologic approach*. 2<sup>nd</sup> Edition, Norwalk, CT, Appleton and Lange, 1992.
10. Bosso JA. Antibiotic resistance *in* bacteria, *in* *Pharmacotherapy Self-Assessment Program*, 2<sup>nd</sup> Edition, Kansas City, MO, American College of Clinical Pharmacy, 1995.
11. Bosso JA. Cystic fibrosis, *in* DiPiro JT et al, *Pharmacotherapy: A pathophysiologic approach*. 3<sup>rd</sup> Edition, Norwalk, CT, Appleton and Lange, 1996.
12. Lindsay CA, Bosso JA. Fundamentals of pharmacokinetics, pharmacodynamics and therapeutic drug monitoring, *in* Feigin RD, Cherry JD, eds., *Textbook of Pediatric Infectious Diseases*. 3<sup>rd</sup> Edition, Philadelphia, PA, WB Saunders Co., 1997.
13. Bosso JA. Cystic fibrosis, *in* DiPiro JT et al, *Pharmacotherapy: A pathophysiologic approach*. 4<sup>th</sup> Edition, Norwalk, CT, Appleton and Lange, 1999.
14. Bosso JA, Milavetz, G. Cystic fibrosis, *in* DiPiro JT et al, *Pharmacotherapy: A pathophysiologic approach*. 5<sup>th</sup> Edition, NYC, McGraw Hill, 2002.

## ARTICLES IN REFEREED JOURNALS:

1. Bosso JA, Chudzik GM. Stevens-Johnson syndrome associated with diphenylhydantoin. *Drug Intell Clin Pharm* 1973;7:336-9.
2. Bosso JA, Pearson RE. Sugar content of selected oral medicinals. *Diabetes* 1973;22:776-84.
3. Bosso JA, Chudzik GM. Cystic fibrosis - the pharmacist's role. *Drug Intell Clin Pharm* 1974;8:58-64.
4. Bosso JA. Bacterial meningitis. *Drug Intell Clin Pharm* 1975;9:242-8.
5. Bosso JA, Pneumocystis carinii pneumonia treated with pentamidine. *Drug Intell Clin Pharm* 1975;9:657-9.
6. Bosso JA. Serving on the health team at summer camp for diabetic children. *J Am Pharm Assoc* 1976;NS16:463-4.
7. Bosso JA. Pseudotumor cerebri associated with drug therapy. *Drug Intell Clin Pharm* 1976;10:566-8.
8. Bosso JA. A course in instructional competence for doctor of pharmacy candidates. *Am J Pharm Ed* 1977;41:288-90.
9. Bosso JA, Jackman J. Acute otitis media. *Drug Intell Clin Pharm* 1977;11:665-71.
10. Higbee MD, Bosso JA. Apnea of prematurity. *Drug Intell Clin Pharm* 1979;13:24-9.
11. Lipman AG, Bair JN, Hibbard FJ, Bosso JA et al. Decentralization of pharmaceutical services without satellite pharmacies. *Am J Hosp Pharm* 1979;36:1513-9.
12. Bosso JA, Mutchie KD. Hypertension in pediatrics. *Drug Intell Clin Pharm* 1979;13:653-63.
13. Hibbard FJ, Bosso JA et al. A time-efficiency study of a decentralized pharmacy system without satellites, *Am J Hosp Pharm* 1981;38:690-2.
14. Mutchie KD, Bosso JA, Higbee MD. Audio-visual instruction in pediatric pharmacy practice. *Am J Pharm Ed* 1981;45:153-5.
15. Garnett WR, Bosso JA et al. Retroactive awarding of doctor of pharmacy degrees to baccalaureate graduates of schools/colleges of pharmacy. *Am J Pharm Ed* 1981;45:396-7.
16. Hart LL, Garnett WR, Bosso JA et al. PD as the uniform designation for pharmacists. *Am J Pharm Ed* 1981;45:397-9.
17. Bosso JA. Experience with a new small volume infusion system in pediatric patients. *Hosp Form* 1982;17:214-22.
18. Higbee MD, Dukes GE, Bosso JA. Patient recall of physician's prescription instructions. *Hosp Form* 1982;17:553-6.

## ARTICLES IN REFEREED JOURNALS (continued):

19. Bosso JA. Clinical evaluation of a new small volume infusion system in ambulatory volunteers. *Am J Intravenous Ther Clin Nutrition* 1982;9:15-22.
20. Bosso JA, Chan GM, Matsen JM. Pharmacokinetics of cefoperazone in preterm neonates. *Antimicrob Agents Chemother* 1983;23:413-5.
21. Bosso JA. The role of the institutional review board in research involving human subjects. *Drug Intell Clin Pharm* 1983;17:828-34.
22. Bosso JA, Saxon BA, Herbst JJ, Matsen JM. Azlocillin pharmacokinetics in patients with cystic fibrosis. *Antimicrob Agents Chemother* 1984;25:630-2.
23. Bosso JA. Considerations of the institutional review board in artificial organ development. *J Contemp Law* 1984;11:61-5.
24. Bosso JA, Stephenson SE, Herbst JJ. Feasibility and cost savings of intravenous administration of aminoglycosides in outpatients with cystic fibrosis. *Drug Intell Clin Pharm* 1985;19:52-4.
25. Bosso JA, Mead RA, Matsen JM, Gooch WM. Agreement between capillary and arterial serum gentamicin concentrations in neonates. *Pediatr Infect Dis* 1985;4:142-4.
26. Foley PT, Bosso JA, Bair JN, Townsend RJ. Compatibility of clindamycin phosphate with either cefotaxime sodium or netilmicin sulfate in small volume parenteral solutions. *Am J Hosp Pharm* 1985;42:839-43.
27. Bosso JA, Spruance SL, Wenerstrom G. Tolerance and percutaneous absorption of topically applied arildone. *J Clin Pharmacol* 1985;25:95-9.
28. Smith PC, Langendijk PNJ, Bosso JA, Benet LZ. Effect of probenecid on the formation and elimination of acyl glucuronides: Studies with zomepirac. *Clin Pharmacol Ther* 1985;38:121-7.
29. Bosso JA, Townsend RJ. Compatibility of clindamycin phosphate with ceftizoxime sodium, cefoxitin sodium, cefamandole nafate and cefazolin sodium in two intravenous solutions. *Am J Hosp Pharm* 1985;42:2211-4.
30. Bosso JA, Townsend PL, Herbst JJ, Matsen JM. Pharmacokinetics and dosage requirements of netilmicin in cystic fibrosis patients. *Antimicrob Agents Chemother* 1985;28:829-31.
31. Douglas JM, Judson FN, Levin MJ, Bosso JA, Spruance SL et al. A placebo controlled trial of topical 8% arildone cream early in recurrent genital herpes. *Antimicrob Agents Chemother* 1986;29:464-7.
32. Marble DA, Bosso JA. Norfloxacin: A quinolone antibiotic. *Drug Intell Clin Pharm* 1986;20:261-6.
33. Marble DA, Bosso JA, Townsend RJ. Compatibility of clindamycin phosphate with aztreonam, ceftazidime sodium, ceftriaxone sodium and piperacillin sodium in two intravenous solutions. *Am J Hosp Pharm* 1986;43:1732-6.
34. Marble DA, Bosso JA, Townsend RJ. Compatibility of clindamycin phosphate with amikacin sulfate at room temperature and with gentamicin sulfate and tobramycin sulfate under frozen conditions. *Drug Intell Clin Pharm* 1986;20:960-3.
35. Bosso JA, Relling MV, Townsend PL, Strand LM. Inpatient variations in aminoglycoside disposition in cystic fibrosis. *Clin Pharm* 1987;6:54-8.
36. Bosso JA, Black PG, Matsen JM. Efficacy of aztreonam in pulmonary exacerbations of cystic fibrosis. *Pediatr Infect Dis* 1987;6:393-7.
37. Bosso JA, Black PG, Matsen JM. Ciprofloxacin versus tobramycin plus azlocillin in pulmonary exacerbations in adult cystic fibrosis patients. *Am J Med* 1987;82(Suppl 4A):180-4.
38. Zbrozek AS, Marble DA, Bosso JA, Townsend RJ. Compatibility and stability of clindamycin phosphate aminoglycoside combinations within polypropylene syringes. *Drug Intell Clin Pharm* 1987;21:806-10.
39. Bosso JA, Saxon BA, Matsen JM. In vitro activity of aztreonam combined with tobramycin and gentamicin against clinical isolates of *Pseudomonas aeruginosa* and *Pseudomonas cepacia* from cystic fibrosis patients. *Antimicrob Agents Chemother* 1987;31:1403-5.
40. Allen JE, Bosso JA, Saxon BA, Matsen JM. Absence of rapidly developing resistance during treatment of cystic fibrosis patients with aztreonam. *Diagn Microbiol Infect Dis* 1987;8:51-5.
41. Marble DA, Bosso JA, Townsend RJ. Compatibility of clindamycin phosphate with aztreonam in polypropylene syringes and with cefoperazone sodium, cefonocid sodium and cefuroxime sodium in partial fill glass bottles. *Drug Intell Clin Pharm* 1988;22:54-7.
42. Bosso JA, Black PG. Efficacy of ciprofloxacin in patients with cystic fibrosis. *Drug Intell Clin Pharm* 1988;22:551-3.

#### ARTICLES IN REFEREED JOURNALS (continued):

43. Bosso JA, Black PG. A controlled trial of aztreonam vs. tobramycin plus azlocillin for acute pulmonary exacerbations of cystic fibrosis. *Pediatr Infect Dis J* 1988;7:171-6.
44. Wright DN, Marble DA, Saxon BA, Johnson CC, Bosso JA, Matsen JM. In vitro inactivation of aminoglycosides by cephalosporin antibiotics. *Arch Path Lab Med* 1988;112:536-8.
45. Zbrozek AS, Marble DA, Bosso JA. Compatibility and stability of ceftazidime sodium, clindamycin phosphate, and gentamicin sulfate in two intravenous solutions. *Drug Intell Clin Pharm* 1988;22:873-5.
46. Bosso JA, Walker KB. Lack of correlation between objective indicators and clinical-response scores during antimicrobial therapy for acute pulmonary exacerbations of cystic fibrosis. *Clin Pharm* 1988;7:897-901.
47. Bosso JA, Allen JE, Matsen JM. Changing susceptibility of *Pseudomonas aeruginosa* isolates from cystic fibrosis patients with the clinical use of newer antibiotics. *Antimicrob Agents Chemother* 1989;33:526-8.
48. Bosso JA. Bacterial resistance to antibiotics: Mechanisms and prevalence in hospitals and nursing homes. *Drug Intell Clin Pharm* 1989;23:556-61.
49. Matsen JM, Bosso JA. The use of aztreonam in the cystic fibrosis patient. *Pediatr Infect Dis J* 1989;8:S117-9.
50. McRorie TI, Bosso JA, Randolph L. Aminoglycoside ototoxicity in cystic fibrosis: Evaluation by high-frequency audiometry. *Am J Dis Child* 1989;143:1328-32.
51. Osato MS, Jensen HG, Trousdale MD, Bosso JA, Borrmann LR, Frank J, Akers P. The comparative activity of ofloxacin and selected ophthalmic antimicrobial agents against ocular bacterial isolates. *Am J Ophthal* 1989;108:380-6.
52. Bosso JA. The use of ciprofloxacin in cystic fibrosis patients. *Am J Med* 1989;87(Suppl 5A):123-7.
53. Bosso JA, Prince RA. Anti-anaerobic antimicrobials: ceftiofur, cefotetan, clindamycin and metronidazole. *Tex Heart Instit J* 1990;17:77-85.
54. Bosso JA, Saxon BA, Matsen JM. In vitro activity of combinations of aztreonam, ciprofloxacin and ceftazidime against clinical isolates of *Pseudomonas aeruginosa* and *Pseudomonas cepacia* from cystic fibrosis patients. *Antimicrob Agents Chemother* 1990;34:487-8.
55. Bosso JA. Fungal infections in pediatric patients. *Pharmacotherapy* 1990;10:150S-3S.
56. Pribble CG, Black PG, Bosso JA, Turner RB. The clinical manifestations of exacerbations of cystic fibrosis associated with nonbacterial infections. *J Pediatr* 1990;117:200-4.
57. Bosso JA, Black PG. The use of aztreonam in pediatrics. A Review. *Pharmacotherapy* 1991;11:20-5.
58. Bosso JA, Saxon BA, Matsen JM. Comparative activity of cefepime, alone and in combination, against clinical isolates of *Pseudomonas aeruginosa* and *Pseudomonas cepacia* from cystic fibrosis patients. *Antimicrob Agents Chemother* 1991;35:783-4.
59. Bosso JA, Liptak CA, Seilheimer DK, Harrison GM. Toxicity of colistin in cystic fibrosis patients. *DICP. Ann Pharmacother* 1991;25:1168-70.
60. Paap CM, Bosso JA. Treatment options for the pharmacologic treatment of neonatal meningitis. *Drugs* 1992;43:700-712.
61. Bosso JA. Advances in the pharmacotherapy of cystic fibrosis. *J Clin Pharm Ther* 1992;17:263-70.
62. Bosso JA, Prince RA, Fox JL. Stability of injectable ondansetron solutions stored at three temperatures. *Am J Hosp Pharm* 1992;49:2223-5.
63. Lindsay CA, Bosso JA. Optimization of antibiotic therapy in cystic fibrosis patients. *Clin Pharmacokinet* 1993;24:496-506.
64. Huls CE, Prince RA, Seilheimer DK, Bosso JA. Pharmacokinetics of cefepime in cystic fibrosis patients. *Antimicrob Agents Chemother* 1993;37:1414-6.
65. Prince RA, Bosso JA. The role of biopharmaceutics and pharmacokinetics in drug therapy. *US Pharmacist* 1993 (Oct): 98-104.
66. Bosso JA, Prince RA, Fox JL. Compatibility of two concentrations of ondansetron with fluconazole, ceftazidime, aztreonam and ceftazidime solutions under simulated Y-site conditions. *Am J Hosp Pharm* 1994;51:389-91.
67. Prince RA, Bosso JA. Resistance to beta-lactam antimicrobial agents. *J Infect Dis Pharmacother* 1995 (1);1:25-47..

## ARTICLES IN REFEREED JOURNALS (continued):

68. Bosso JA. Tuberculosis in pediatric patients. *J Infect Dis Pharmacother* 1995 (1);1:59-74.
69. Annaissie EJ, Kontoyiannis DP, Huls C, Vartivarian SE, Karl C, Prince RA, Bosso JA, Bodey GP. Safety, plasma concentrations, and efficacy of high-dose fluconazole in invasive mold infections. *J Infect Dis* 1995;172:599-602.
70. Shwed JA, Ceresia ML, Taylor AJ, Bosso JA. Lack of effect of clavulanic acid on aminoglycoside inactivation by ticarcillin. *J Infect Dis Pharmacother* 1995 (2);1:35-43.
71. Bosso JA, Taylor AJ, Fox JL, Weber TR, Sabados BK. Compatibility of anakinra with ondansetron, ceftazidime, cefuroxime and ranitidine solutions under simulated Y-site conditions. *J Infect Dis Pharmacother* 1995 (2);1:67-75.
72. Friedrich LV, White RL, Burgess DS, Warkentin DI, Bosso JA. Comparative stability of imipenem and meropenem in Mueller-Hinton broth at room temperature, during incubation, and during frozen storage. *J Infect Dis Pharmacother* 1995 (2);1:21-34.
73. Bosso JA. Pharmacotherapeutic management of the infectious and inflammatory complications of cystic fibrosis. *J Infect Dis Pharmacother* 1995 (3);1:59-77.
74. Bosso JA, Taylor AJ, White RL, Sabados BK. Compatibility of two concentrations of recombinant human interleukin-1 receptor antagonist with selected antimicrobial agents. *J Infect Dis Pharmacother* 1995 (4);1:45-54.
75. White R, Friedrich L, Burgess D, Warkentin D, Bosso J. Comparative in vitro pharmacodynamics of imipenem and meropenem against *P. aeruginosa*. *Antimicrob Agents Chemother* 1996;40:904-8
76. Cramer GW, Bosso JA. The role of dornase alfa (rhDNase) in the treatment of cystic fibrosis. *Ann Pharmacother* 1996;30:656-61.
77. Bosso JA, Liu Q, Evans WE, Relling MV. CYP2D6, N-acetylation, and xanthine oxidase activity in cystic fibrosis. *Pharmacotherapy* 1996;16:749-53.
78. Burgess DS, White RL, Friedman RJ, Bosso JA. Impact of different methodologies on the estimation of antibiotic tissue penetration: Determination of cefmetazole penetration into bone and soft tissue. *J Infect Dis Pharmacother* 1996;2(1):15-28.
79. Bosso JA. Prevention and control of nosocomial infections. *J Infect Dis Pharmacother* 1996;2(1):59-71.
80. White RL, Burgess DS, Manduru M, Bosso JA. A comparison of three different in vitro methods of detecting synergy: Time-kill, checkerboard and E test. *Antimicrob Agents Chemother* 1996;40:1914-8.
81. Manduru M, Fariello A, White RL, Fox JL, Bosso JA. Compatibility and stability of admixtures of ceftazidime sodium and teicoplanin in peritoneal dialysis solution. *Am J Health-Syst Pharm* 1996;53:2731-4.
82. Hall PD, Yui D, Lyons S, Bosso JA. Y-site compatibility of filgrastim with various antimicrobials. *Am J Health-Syst Pharm* 1997;54:185-9.
83. Bosso JA, Stringer KA, Hammond RW. Pharmacotherapy specialty certification examination. V. Further experience and refinement. *Pharmacotherapy* 1997;17:399-406.
84. Spindler SA, Bosso J, Hak H, Hammond R, Kradjan W, Poirier T, Wagner M. Report of the task force concerning board certification requirements for pharmacy practice faculty. *Am J Pharm Ed* 61:213-6, 1997.
85. Manduru M, Mihm LB, White RL, Friedrich LV, Flume PA, Bosso JA. In vitro pharmacodynamics of ceftazidime against *Pseudomonas aeruginosa* isolates derived from cystic fibrosis patients. *Antimicrob Agents Chemother* 1997;41:2053-6.
86. Manduru M, Mihm LB, White RL, Friedrich LV, Bosso JA. A new in vitro model for the assessment of antimicrobial pharmacodynamics: Description and assessment of performance characteristics. *J Infect Dis Pharmacother* 1997;2(3):29-46.
87. Manduru M, Mihm LB, White RL, Friedrich LV, Flume PA, Bosso JA. Comparative bactericidal activity of ceftazidime against isolates of *Pseudomonas aeruginosa* as assessed in an in vitro pharmacodynamic model versus the traditional time-kill method. *Antimicrob Agents Chemother* 1997;41:2527-32.
88. Bosso JA. New and emerging fluoroquinolone antibiotics. *J Infect Dis Pharmacother* 1998;2(4):61-76.
89. Bosso JA. Concepts and controversies in the prevention and treatment of cerebrospinal fluid shunt infections in pediatric patients. *J Infect Dis Pharmacother* 1998;2(4):27-37.

## ARTICLES IN REFEREED JOURNALS (continued):

90. White RL, Burgess DS, Friedrich LV, Walker MA, Bosso JA. Comparison of various susceptibility testing methods of  $\beta$ -lactam/ $\beta$ -lactamase inhibitor combinations based upon predicted in vivo serum concentrations. *J Infect Dis Pharmacother* 1998;3(1):13-26.
91. Friedrich LV, White RL, Bosso JA. Impact Of Multiple Antimicrobial Usage On Changes In Susceptibility Of Gram-Negative Aerobes. *Clin Infect Dis* 1999;28:1017-24.
92. Bosso JA. An overview of the new fluoroquinolone antibiotics. *J Infect Dis Pharmacother* 1999;3(3):1-8.
93. Bosso JA, Bonapace RC, Flume PA, White RL. A pilot study of the efficacy of constant infusion ceftazidime in the treatment of endobronchial infections in adults with cystic fibrosis. *Pharmacotherapy* 1999;19:620-6.
94. Bosso JA. Bacterial resistance and economic factors in assessing the use of newer antimicrobial agents for respiratory tract infections. *J Infect Dis Pharmacother* 2000;4(2):45-53.
95. Bonapace CR, White RL, Friedrich LV, Norcross ED, Bosso JA. Pharmacokinetics of cefepime in patients with thermal burn injury. *Antimicrob Agents Chemother* 1999;43:2848-54.
96. White RL, Friedrich LV, Mihm LB, Bosso JA. assessment of the relationship between antimicrobial usage and susceptibility: Differences between the hospital and specific patient care areas. *Clin Infect Dis* 2000;31:16-23.
97. Bonapace, CR, White RL, Friedrich LV, Bosso JA. Evaluation of antibiotic synergy against *Acinetobacter baumannii*: A comparison with E-test, time-kill, and checkerboard methods. *Diagn Microbiol Infect Dis* 2000;38:43-50.
98. White RL., Friedrich LV, Manduru M, Mihm LB, Bosso JA. Comparative in vitro pharmacodynamics of imipenem and meropenem against ATCC strains of *Escherichia coli*, *Staphylococcus aureus* and *Bacteroides fragilis*. *Diagn Microbiol Infect Dis* 2001;39:39-47.
99. White RL, Enzweiler, KA, Friedrich LV, Wagner D, Hoban D, , JA. Comparative Activity of Gatifloxacin and Other Antibiotics Against 4009 Clinical Isolates of *Streptococcus pneumoniae* in the United States During 1999-2000. *Diagn Microbiol Infect Dis* 2002;43:207-17.
100. Bonapace CR, White RL, Friedrich LV, Bosso JA. Differences in antimicrobial drug exposure in patients with varying degrees of renal function based upon recommendations from dosing references. *Pharmacotherapy* 2002;22:1097-1104.
101. Bonapace CR, Friedrich LV, Bosso JA, White RL,. Determination of antibiotic effect in an in vitro pharmacodynamic model: comparison with an established animal model of infection. *Antimicrob Agents Chemother* (in press).
102. Bosso JA. Antibiotic Selection Strategies for Acute Exacerbations of Chronic Bronchitis: Issues and Challenges. *Consultant* (in press).
103. Bonapace CR, Bosso JA, Friedrich LV, White RL. Comparison of Methods of Interpretation of Checkerboard Synergy Testing. *Diagn Microbiol Infect Dis* (in press).

## EDITORIALS:

### Invited:

1. Bosso JA. Controlling pneumococcal resistance to penicillin. *Am J Health-Syst Pharm* 1997;54:527.
2. Bosso JA. Infectious diseases pharmacotherapy. An area of added qualification? *J Infect Dis Pharmacother* 1997;17:1048-9.
3. Bosso JA, Hardin TC. Added qualifications for pharmacy specialists: an editorial perspective. *Ann Pharmacother* 1997;31:1535-6.
4. Bosso JA. The dilemma of increasing bacterial resistance. *J Pediatr Pharmacol Therap* 2001;6:291-3.

### Contributed:

1. Bosso JA. Universal Pharm.D. versus the real question. *Drug Intell Clin Pharm* 1979;12:370.
2. Bosso JA. Should pulmonary exacerbations in cystic fibrosis be treated with antibiotics? *Drug Intell Clin Pharm* 1984;18:825-6.
3. Nappi J, Bosso JA. Clinical pharmacy and clinical research. *Drug Intell Clin Pharm* 1988;22:804-6.
4. Bosso J. Academic pharmacy practice and research. *DICP Ann Pharmacother* 1991;25:1129-31.

5. Bosso JA. Another new journal? J Infect Dis Pharmacother 1995;1:1-2.
6. Bosso JA. Is pharmacotherapy a specialty? Pharmacotherapy 1997;17:413-4.
7. Bosso JA. Is Pharmacotherapy a specialty? and the emperor's new clothes - author's reply. Pharmacotherapy 1997;2:1-3.

## MISCELLANEOUS PUBLICATIONS

1. Bosso JA. Comment on the clinical use of theophylline. Drug Intell Clin Pharm 1973;7:358. (Communication)
2. Bosso JA, Higbee MD. Topics in pediatric clinical pharmacy, Part I. Utah Pharm Digest 1975;84:7-8.
3. Bosso JA, Higbee MD. Topics in pediatric clinical pharmacy, Part II. Utah Pharm Digest 1975;84:3-4.
4. Bosso JA. Bacterial meningitis. Drug Intell Clin Pharm 1975;9:457. (Communication)
5. Bosso JA. Update on treatment of *Pneumocystis carinii* pneumonia. Drug Intell Clin Pharm 1977;11:370. (Communication)
6. Bosso JA. Cystic fibrosis. Voices (ASHP audiotape program), published by Teach'em Inc. 1980
7. Bosso JA. Employment as a bias. Drug Intell Clin Pharm 1987;21:1016. (Communication)
8. Bosso JA, Gentry LO, Neu HC, Pankey GA. A review of ciprofloxacin's effectiveness, clinical uses, and other P&T committee concerns. Hosp Form 1988;23(Suppl B):10-18.
9. Bosso JA. Antimicrobials on the horizon: New parenteral cephalosporins. Hosp Ther 1989;14:33-47.
10. Bosso JA, Prince RA. Vaccine Developments. ACCP Report 1990;4:3-4.
11. Bosso JA. Clindamycin stability, DICP, Ann Pharmacother 1990;24:1008-9.
12. Prince RA, Bosso JA. Azithromycin and clarithromycin: New macrolides. Infectious Disease News 1992;5:19.
13. Weart CW, Bosso JA, Gums JG. Adverse consequences of inappropriate drug substitution. Skin & Aging. July Suppl, 1999.

## ABSTRACTS:

1. Hibbard FJ, Bosso JA, Cheminant RL. Implementation of decentralized pharmacy services at the University of Utah Medical Center, Proceedings of the 13<sup>th</sup> Annual ASHP Midyear Clinical Meeting, p.28 Abstract #160-P, 1978.
2. Higbee MD, Dukes GE, Bosso JA. Patient interpretation of physician's prescription instructions, Proceedings of the 13<sup>th</sup> Annual ASHP Midyear Clinical Meeting, p.109 Abstract #205-P, 1978.
3. Bosso JA. Cystic fibrosis, Proceedings of the 14<sup>th</sup> Annual ASHP Midyear Clinical Meeting, p.44 Abstract #6-S, 1979.
4. Bosso JA. Clinical evaluation of a new small volume infusion system in normal ambulatory volunteers, Proceedings of the 14<sup>th</sup> Annual ASHP Midyear Clinical Meeting, p.81 Abstract #16-P, 1979.
5. Hibbard FJ, Bosso JA, Sward LW, Baum S. A time-efficiency study of decentralized pharmacy services, Proceedings of the 14<sup>th</sup> Annual ASHP Midyear Clinical Meeting, p.86 Abstract #34-P, 1979.
6. Bosso JA, Huckendubler SE, Herbst JJ. Feasibility study of outpatient intravenous aminoglycoside administration, ACCP 4<sup>th</sup> Annual Meeting, Drug Intell Clin Pharm 1983;17:435.
7. Gooch WM, Bosso JA, Smith LH, Rakhsha G. Accurate, simple microbiologic assay for ceftazidime in body fluids, Proceedings of the 23<sup>rd</sup> ICAAC, p.100 Abstract #113, 1983.
8. Foley P, Bair JN, Bosso JA, Townsend RJ. Compatibility and stability of clindamycin, cefotaxime and netilmicin in small volume intravenous solutions, Proceedings of the 41<sup>st</sup> ASHP Annual Meeting, p.109, Abstract #P-39, 1984.
9. Resta S, Luby J, Spruance SL, Bosso JA. Topical arildone vs acyclovir for therapy of cutaneous HSV infections in immunocompromised patients, Proceedings of the 24<sup>th</sup> ICAAC p.313 Abstract #1256, 1984
10. Bosso JA, Townsend RJ. The stability and compatibility of clindamycin with four cephalosporins, Proceedings of the 19<sup>th</sup> Annual ASHP Midyear Clinical Meeting, p.129 Abstract #P-257, 1984.
11. Bosso JA et al. Correlation between capillary and arterial serum gentamicin concentrations in neonates, 86<sup>th</sup> Annual ASCPT Meeting, Clin Pharmacol Ther 1985;37:183.

**ABSTRACTS** (continued):

12. Bosso JA et al. Pharmacokinetics and dosage requirements of netilmicin in cystic fibrosis patients, 86<sup>th</sup> Annual ASCPT Meeting, Clin Pharmacol Ther 1985;37:183.
13. Gooch WM, Swenson E, Bosso JA, Minton S. Neonatal pharmacokinetic characteristics of ceftizoxime, 86<sup>th</sup> Annual ASCPT Meeting, Clin Pharmacol Ther 1985;37:199.
14. Smith PC, Langendijk PNJ, Bosso JA, Benet LZ. Effect of probenecid on the disposition of zomepirac and zomepirac glucuronide, 86<sup>th</sup> Annual ASCPT Meeting, Clin Pharmacol Ther 1985;37:229.
15. Zbrozek AS, Marble DA, Bosso JA et al. Compatibility and stability of clindamycin phosphate and gentamicin sulfate in a polypropylene syringe, Proceedings of the 42<sup>nd</sup> Annual ASHP Meeting, p.142 Abstract #P78D, 1985.
16. Daly JA, Saxon BA, Bosso JA, Thomas T, Matsen JM. Susceptibility of *Haemophilus influenzae* to first, second and third generation cephalosporins, Recent Advances in Chemotherapy 1985;4:1061-2.
17. Zbrozek AS, Marble DA, Bosso JA et al. Compatibility and stability of clindamycin phosphate with tobramycin sulfate in polypropylene syringes, Proceedings of the 20<sup>th</sup> ASHP Midyear Clinical Meeting, p.90 Abstract #P-170D, 1985.
18. Bosso JA. Failure of traditional pharmacokinetic dosing methods for aminoglycosides in cystic fibrosis patients, 1986 Western Society for Pediatric Research Annual Meeting, Clin Res 1986;34:115A.
19. Marble DA, Zbrozek AS, Bosso JA et al. Compatibility and stability of clindamycin phosphate, cefazolin sodium and gentamicin sulfate in two intravenous solutions, Proceedings of the 43<sup>rd</sup> Annual ASHP Meeting, p.138 Abstract #P-17D, 1986.
20. Bosso JA, Black PG, Matsen JM. Efficacy of aztreonam in cystic fibrosis. 7<sup>th</sup> Annual ACCP Meeting, Drug Intell Clin Pharm 1986;20:452.
21. Allen JE, Bosso JA, Saxon BA, Matsen JM. Susceptibility of clinical isolates of *Pseudomonas aeruginosa* from cystic fibrosis patients to ciprofloxacin and 10 other antibiotics, Proceedings of the 87<sup>th</sup> Annual ASM Meeting, p.1 Abstract #A-3, 1987.
22. Allen JE, Bosso JA, Saxon BA, Matsen JM. Absence of resistance and cross-resistance of *Pseudomonas aeruginosa* during aztreonam therapy in cystic fibrosis patients, Proceedings of the 87<sup>th</sup> Annual ASM Meeting, p.10 Abstract #A-55, 1987.
23. Bosso JA, Black PG, Pryka RD, Matsen JM. Aztreonam vs. tobramycin plus azlocillin in cystic fibrosis. 88<sup>th</sup> Annual ASCPT Meeting, Clin Pharmacol Ther 1987;41:192.
24. Bosso JA, Black PG. Efficacy of ciprofloxacin in adults with cystic fibrosis. 8<sup>th</sup> Annual ACCP Meeting, Drug Intell Clin Pharm 1987;21:8A.
25. Bosso JA, Saxon BA, Matsen JM. Synergy of aztreonam-aminoglycoside combinations against clinical isolates of *Pseudomonas aeruginosa* and *Pseudomonas cepacia* from cystic fibrosis patients, 8<sup>th</sup> Annual ACCP Meeting, Drug Intell Clin Pharm 1987;21:9A.
26. Bosso JA, Black PG, Matsen JM. A controlled trial of aztreonam vs. tobramycin and azlocillin in cystic fibrosis. Proceedings of the 27<sup>th</sup> ICAAC, p.236 Abstract #803, 1987.
27. Bosso JA, Black PG. A comparative trial of aztreonam and tobramycin plus azlocillin for acute pulmonary exacerbations of cystic fibrosis, Proceedings of the 10<sup>th</sup> International Cystic Fibrosis Congress, p.112 Abstract #R©17, 1988.
28. Bosso JA, Walker K. Clinical and laboratory measurements of response to antibiotic therapy in cystic fibrosis, 9<sup>th</sup> Annual ACCP Meeting, Pharmacotherapy 1988;8:129.
29. McRorie TI, Bosso JA. Cumulative ototoxicity of aminoglycosides in cystic fibrosis patients: An evaluation by high frequency audiometry, 9<sup>th</sup> Annual ACCP Meeting, Pharmacotherapy 1988;8:129.
30. Bosso JA, Matsen JM. Changing susceptibility of *Pseudomonas aeruginosa* from cystic fibrosis patients with the clinical use of ciprofloxacin, aztreonam and ceftazidime, Proceedings of the 28<sup>th</sup> ICAAC, p.223 Abstract #649, 1988.
31. Pribble CG, Black PG, Bosso JA, Turner RB. Clinical relevance of a positive CRP during acute pulmonary exacerbations of cystic fibrosis, 1989 WSPR, Clin Res 1989;37:146A.
32. Bosso JA, Evans WE. Debrisoquine-oxidation phenotype in cystic fibrosis patients. 90<sup>th</sup> Annual ASCPT Meeting, Clin Pharmacol Ther 1989;45:138.

**ABSTRACTS** (continued):

33. Bosso JA, Saxon BA, Matsen JM. In vitro activity of combinations of aztreonam, ceftazidime and ciprofloxacin against clinical isolates of *Pseudomonas aeruginosa* from cystic fibrosis patients, Proceedings of the 29<sup>th</sup> ICAAC, p.116 Abstract #95, 1989.
34. Turner RB, Pribble CG, Black PG, Bosso JA. Influenza as a cause of severe pulmonary exacerbations in patients with cystic fibrosis, Proceedings of the 29<sup>th</sup> ICAAC, p.198 Abstract #579, 1989.
35. Bosso JA, Evans WE. Debrisoquin-type oxidation and N-acetylation phenotypes in cystic fibrosis patients, 3<sup>rd</sup> Annual North American Cystic Fibrosis Conference, *Pediatr Pulmonol* 1989; Suppl 4:157-8.
36. Bosso JA, Saxon BA, Matsen JM. Comparative activity of cefepime against clinical isolates of *Pseudomonas aeruginosa* and *P. cepacia* from cystic fibrosis patients. Proceedings of the 90<sup>th</sup> ASM Annual Meeting, Abstract #A47, 1990.
37. Bosso JA, Liptak CA, Seilheimer DK, Harrison GM. Toxicity of intravenous colistin in cystic fibrosis patients. 4<sup>th</sup> Annual North American Cystic Fibrosis Conference, *Pediatr Pulmonol* 1990;(Suppl 5):244.
38. Bosso JA, Saxon BA, Matsen JM. In vitro synergy with cefepime and ciprofloxacin, aztreonam or tobramycin against *Pseudomonas aeruginosa* and *Pseudomonas cepacia* from cystic fibrosis patients, Proceedings of the 30<sup>th</sup> ICAAC, p.234 Abstract #889, 1990.
39. Tracewell WG, Bosso JA, Gwilt PR. Population pharmacokinetics of cefoperazone in neonates, Proceedings of the Midwest Regional Meeting of the AAPS, 1991.
40. Bosso JA, Prince RA, Fox JL. Stability of ondansetron under various storage conditions, Proceedings of the 26<sup>th</sup> ASHP MCM, p.171 Abstract #P-384E, 1991.
41. Huls CE, Seilheimer DK, Prince RA, Kaplan SL, Bosso JA. Cefepime pharmacokinetics in cystic fibrosis patients, Proceedings of the ACCP Winter Practice and Research Forum, p.177 Abstract #25, 1992.
42. Huls CE, Anaissie E, Bodey GR, Prince RA, Bosso JA. Serum concentrations relationships during high-dose i.v. fluconazole therapy, Proceedings of the ACCP Winter Practice and Research Forum, p.182 Abstract #62, 1992.
43. Huls CE, Seilheimer DK, Prince RA, Bosso JA. Cefepime pharmacokinetics in cystic fibrosis vs. non-cystic fibrosis patients, Proceedings of the 11<sup>th</sup> International Cystic Fibrosis Congress, Abstract #TP18, 1992. (also published in *Pharmacotherapy* 1992;12:506, abs #72E)
44. Anaissie E, Kontoyiannas D, Huls C, Prince R, Bosso JA, Bodey GP. Efficacy, safety and pharmacokinetics of high dose fluconazole in patients with fungal infections. Proceedings of the 32<sup>nd</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, p.215 Abstract #626, 1992.
45. Bosso JA, Prince RA, Fox JL. Compatibility of two concentrations of ondansetron with fluconazole, ceftazidime, aztreonam and cefazolin solutions under simulated Y-site conditions, Proceedings of the 27<sup>th</sup> ASHP MCM, p.101 Abstract #P-166E, 1992.
46. White RL, Burgess DS, Bosso JA, Walker M. Comparison of susceptibility testing methods of beta-lactamase inhibitor combinations based on human pharmacokinetics, 14<sup>th</sup> Annual ACCP Meeting, *Pharmacotherapy* 1993;13:279.
47. Prince RA, Franklin DJ, Bosso JA, Huls CE, Shyu WC. A single dose pharmacokinetic and safety study of two dose levels of cefprozil in patients undergoing tonsillectomy/adenoidectomy, 14<sup>th</sup> Annual ACCP Meeting, *Pharmacotherapy* 1993;13:279.
48. Bosso JA, Taylor AJ, Sabados BK, Jacobson T, Weber T, Fox JL. Compatibility of recombinant human interleukin-1 receptor antagonist with ondansetron, ceftazidime, cefuroxime and ranitidine solutions under simulated Y-site conditions, Proceedings of the 28<sup>th</sup> ASHP MCM, p.145 Abstract #P-307E, 1993.
49. Burgess DS, White RL, Bosso JA. Effects of intracellular fluid dilution on estimates of cefmetazole tissue concentrations, 15<sup>th</sup> Annual ACCP Meeting, *Pharmacotherapy* 1994;14:363.
50. Bosso JA, Taylor AJ, Sabados K, White RL, Jacobson T, Chang B. Compatibility of interleukin-1 receptor antagonist (rhIL-1ra) with various antibiotics under simulated Y-site conditions. 1995 ACCP Winter Practice and Research Forum, *Pharmacotherapy* 1995;15:114-5.
51. White RL, Burgess DS, Bosso JA. Comparative pharmacodynamic analysis of oral beta-lactams. 1995 ACCP Winter Practice and Research Forum, *Pharmacotherapy* 1995;15:113.
52. White RL, Burgess DS, Manduru M, Bosso JA. Comparison of an epsilometer test (ET) method of antimicrobial synergy testing with checkerboard (CB) and time-kill (TK) methods. Proceedings of the 95<sup>th</sup> General ASM Meeting, p. 60 Abstract #C343, 1995.

## ABSTRACTS (continued):

53. Hall PD, Yui D, Lyons S, Bosso JA. Y-site compatibility of filgrastim with various antimicrobials. 16<sup>th</sup> ACCP Annual Meeting, Pharmacotherapy 1995;15:371.
54. White RL, Burgess DS, Manduru M, Friedrich LV, Bosso JA. Comparison of in vitro activity of antimicrobial combinations utilizing an area under kill curve (AUKC) technique. 19<sup>th</sup> ICC, Can J Infect Dis 1995;6(Suppl C):474C.
55. White RL, Manduru M, Friedrich LV, Bosso JA. Comparative in vitro pharmacodynamics of imipenem and meropenem during time-kill testing. Proceedings of the 35<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, p.18 Abstract #A96, 1995.
56. Manduru M, Fariello A, White RL, Bosso JA. Compatibility and stability of admixtures of ceftazidime sodium and teicoplanin in peritoneal dialysis solution, International Pharmaceutical Abstracts, p. 2357 Abstract #3213106, 1995.
57. Manduru M, White RL, Friedrich LV, Mihm L, Flume P, Bosso JA. Differences in concentration dependent bactericidal activity among *Pseudomonas aeruginosa* isolates from cystic fibrosis patients, Pharmacotherapy 1996;16:132.
58. Manduru M, White RL, Friedrich LV, Mihm LB, Flume P, Bosso JA. Evaluation of differences in concentration dependent bactericidal activity in cystic fibrosis-derived *Pseudomonas aeruginosa* in an in vitro model. Pharmacotherapy 1996;16:521.
59. Manduru M, Mihm LB, White RL, Friedrich LV, Flume PA, Bosso JA. Concentration-dependent bactericidal activity of constant infusion ceftazidime in cystic fibrosis-derived *Pseudomonas aeruginosa* in an in vitro pharmacodynamic model. Pediatr Pulmonol 1996;(Suppl 13):293.
60. Bosso JA. Antimicrobial resistance in the United States: Status report. Int Pharm Abstr 1996;21:2317-8.
61. Mihm LB, Friedrich LV, White RL, Manduru M, Bosso JA. Comparative pharmacodynamics of levofloxacin, ofloxacin, and ciprofloxacin against nosocomial pathogens. Proceedings of the 97<sup>th</sup> ASM General Meeting, Abstract #A152, 1997.
62. White RL, Friedrich LV, Mihm LB, Bosso JA. Evaluation of changes in susceptibility of Gram-negative aerobes: Pitfalls in examining only single drug relationships. Proceedings of the 37<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, p.50 Abstract #C26, 1997.
63. Friedrich LV, White RL, Yarbrough D, Rinaldi MG, Bosso JA. Alterations of fluconazole pharmacokinetics in severely burned patients. Pharmacotherapy 1997;17:1097.
64. Mihm LB, White RL, Friedrich LV, Bosso JA. Assessment of the relationship between antimicrobial usage and susceptibility: differences between the hospital and specific patient care areas. Pharmacotherapy 1997;17:1130.
65. Bonapace CR, Friedrich LV, White RL, Norcross DE, Mihm LB, Bosso JA. Pharmacokinetics of cefepime in patients with thermal injury. Pharmacotherapy 1998;18:439.
66. Bonapace CR, White RL, Friedrich LV, Mihm LB, Bosso JA. Comparative activity of trovafloxacin and tobramycin in combination with piperacillin and cefepime against clinical isolates of *Acinetobacter baumannii* assessed by three different methods. Proceedings of the 98<sup>th</sup> General Meeting of the American Society for Microbiology, Abstract #12554, 1998.
67. Bonapace D, White R, Friedrich L, Bosso J. Variability in antimicrobial dosing and pharmacodynamic profiles based on recommendations from standard clinical references. Proceedings of the 38<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, p. 33 Abstract A-105, 1998.
68. Bosso J, Bonapace C, White R, Friedrich L, Cappelletty D, Mercier R, Houlihan H, Aeschliman J, Rybak M. Differences in antimicrobial effect determined with three in vitro pharmacodynamic models. Proceedings of the 38<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, p. 43 Abstract A-134, 1998.
69. Bonapace CR, Flume PA, White RL, Bosso JA. Comparative efficacy of continuous infusion ceftazidime in adults with cystic fibrosis. Pharmacotherapy 1998;18:1164.
70. Bonapace CR, White RL, Bosso JA. Differences in fluoroquinolone pharmacodynamic profiles against common pathogens. Pharmacotherapy 1999;19:488.
71. Bonapace CR, White RL, Friedrich LV, Bosso JA. Comparison of methods of interpretation with checkerboard, synergy testing against 10 clinical isolates of *Acinetobacter baumannii*. Proceedings of the 99<sup>th</sup> General Meeting of the American Society for Microbiology, p 18 Abstract A-87, 1999.

## ABSTRACTS (continued):

72. Bonapace CR, White RL, Friedrich LV, Bosso JA. Determination of antibiotic effect in an in vitro model: Comparison with an established animal model. Proceedings of the 39<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, p. 26 Abstract #998, 1999.
73. Bonapace CR, White RL, Lorenz KR, Bosso JA. Worldwide trends in fluoroquinolone susceptibility patterns. Proceedings of the 39<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, p. 180 Abstract #2261, 1999.
74. Bonapace CR, Lorenz KR, Bosso JA, White RL. Evaluation of factors influencing the estimation of creatinine clearance in burn patients. *Pharmacotherapy* 2000;20:341-2.
75. Bonapace CR, Lorenz KR, Bosso JA, White RL. Organism and drug specific variability in the MIC<sub>50</sub> and MIC<sub>90</sub> values of fluoroquinolones. Proceedings of the 100<sup>th</sup> American Society for Microbiology General Meeting, p. 23 Abstract #A91, 2000
76. Bonapace CR, White RL, Friedrich LV, Bosso JA. Differences in fluoroquinolone MICs between Europe and North American against 16 bacterial species. Proceedings of the 100<sup>th</sup> American Society for Microbiology General Meeting, p. 201 Abstract #C301, 2000.
77. Bonapace CR, Lorenz KR, Bosso JA, White RL. Use of different measures of drug usage in assessing antibiotic use/susceptibility relationships. Proceedings of the 40<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, p.403 Abstract #98, 2000.
78. Bonapace CR, Lorenz KR, Bosso JA, White RL. Quantitation of increasing resistance to fluoroquinolones in N. America, Europe, and Asia, 1982-2000. Proceedings of the 40<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, p.403 Abstract #99, 2000.
79. Bonapace CR, Lorenz KR, Fowler JA, Bosso JA, White RL. Differences in fluoroquinolone pharmacodynamics against recent isolates of 20 different bacterial species. Proceedings of the 40<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, p.9 Abstract #297, 2000.
80. Bonapace CR, Lorenz KR, Bosso JA, White RL. Cost of therapy with fluoroquinolones in patient populations with various distributions of renal function. Proceedings of the 40<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, p.504 Abstract #118, 2000.
81. Bonapace CR, Lorenz KR, Bosso JA, White RL. Effect of impaired renal function on fluoroquinolone pharmacodynamics against streptococci. *Pharmacotherapy* 2000;20:1252.
82. Bonapace CR, Lorenz KR, Fowler JG, Bosso JA, White RL. Quantitative assessment of relationships between antibiotic use and susceptibility of Gram-negative aerobes over an eight year period. *Pharmacotherapy* 2000;20:1252.
83. Enzweiler KA, Lorenz KR, Bosso JA, White RL. Relationships between antibiotic use and the rates of isolation and antibiotic susceptibility of Gram-positive bacteria. *Pharmacotherapy* 2001;21:375-6.
84. Enzweiler KA, Lorenz K, Bosso JA, White RL. Comparative variability in MIC<sub>90</sub> values from single vs. multicenter trials. Proceedings of the 101<sup>st</sup> American Society for Microbiology General Meeting, p 135 Abstract A-87, 2001.
85. Enzweiler KA, Lorenz KR, Bosso JA, White RL. Decreasing susceptibility to fluoroquinolones over time: differences in geographic areas. *Pharmacotherapy* 2001;21:1274.
86. Enzweiler KA, Bosso JA, White RL. Comparative carbapenems pharmacodynamics against common Gram-positive and Gram-negative organisms. *Pharmacotherapy* 2001;21:1274.
87. Enzweiler KA, Lorenz KR, Bosso JA, White RL. Worldwide trends in carbapenems susceptibility patterns, 1985-2000.
88. Enzweiler K, Lorenz K, Bosso J, White R. Comparative fluoroquinolone pharmacodynamics against common Gram positive and Gram negative organisms over a range of creatinine clearance. Proceedings of the 41<sup>st</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, p 28 Abstract #A-2072.
89. White R, Enzweiler K, Friedrich L, Lorenz K, Voit E, Bosso J. Monte Carlo analysis of levofloxacin and gatifloxacin pharmacodynamics using expected dosing in a patient population with varying degrees of renal function snf 4,738 recent clinical isolates of *Streptococcus pneumoniae*. Proceedings of the 41<sup>st</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, p 28 Abstract #A-2073.

## ABSTRACTS (continued):

90. White R, Friedrich L, Enzweiler K, Lorenz K, Bosso J, Wagner D. Assessment of the potential for city-wide antibiograms: differences in in vitro activity against *Streptococcus pneumoniae* within major metropolitan areas in the United States. Proceedings of the 41<sup>st</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, p 143 Abstract #C2-2110.
91. Enzweiler K, Lorenz K, Bosso J, White R. Agreement among different markers of antibiotic use over and eight year period. Proceedings of the 41<sup>st</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy, p 410 Abstract #K-1199.
92. White RL, Enzweiler KA, Bosso JA. Evaluation of variability in MIC<sub>90</sub> values for single vs multi-center trials. *Pharmacotherapy* 2002;22:412.

## CURRENT EXTRAMURAL GRANTS/FUNDING:

- Effects of changing renal function, as they relate to labeled and theoretical dosing adjustments, on the pharmacodynamics and pharmacoeconomics of fluoroquinolone therapy, Co-principal investigator, 2000 – (funded – Bayer; \$14,500).
- Variation in fluoroquinolone pharmacodynamics with reported ranges in minimal inhibitory concentrations and pharmacokinetics, Co-principal investigator, 2000 – (funded – Bristol-Myers Squibb; \$10,000).
- Infectious Diseases Pharmacotherapy CE Program – 2002, Principal investigator, 2002 (funded – Pharmacia; \$32,000)
- Infectious Diseases Pharmacotherapy Workshop – 2002 Co-principal investigator, 2002 (funded – Bayer; \$25,000)
- Comparison of pharmacodynamic activity of gatifloxacin and levofloxacin against *Streptococcus pneumoniae* using Monte Carlo Analysis, Co-principal investigator, 2001- (funded – Bristol-Myers Squibb; \$28,191).
- Assessment of susceptibility of *Streptococcus pneumoniae* to fluoroquinolones, Co-principal investigator, 2001-2 (funded – Bristol-Myers Squibb; \$8,000).
- Assessment of susceptibility trends in *Streptococcus pneumoniae* to macrolide and ketolide antibiotics, Co-principal investigator, 2002 – (funded – Aventis; \$23,351).
- A Phase I/II Study of Interferon gamma 1-b (IFN-γ 1b) by Subcutaneous Injection for the Treatment of Patients with Cystic Fibrosis, Co-investigator, 2002 – (funded - InterMune, Inc: \$61,875.00).
- Pharmacokinetics of linezolid in patients with cystic fibrosis, Principal investigator, 2002 – (funded – Pharmacia; \$25,053).

(COMPLETE FUNDING HISTORY AVAILABLE UPON REQUEST)

## PRESENTATIONS (last 3 years):

### INVITED:

135. Antibiotic resistance among respiratory pathogens: Implications for empiric treatment, Horry County Medical Society Monthly Meeting, Myrtle Beach, SC 1999.
136. Current and preventative therapy for Gram-positive infections, Symposium on pharmacotherapy and pharmacoeconomic implications of resistant Gram-positive infections, California Society of Health-system Pharmacists Seminar '99, Long Beach, CA 1999.
137. Clinical pharmacology of respiratory antibiotics, American Society of Consultant Pharmacists 30<sup>th</sup> Annual Meeting, St. Louis, MO 1999.
138. The nature, prevalence, and treatment of infections associated with Gram-positive resistance, Southwest Florida Society of Health-Systems Pharmacists Continuing Education Program, Tampa, FL 1999.
139. Current issues in the treatment of Gram-positive infections, Florida Society of Health-System Pharmacists Spring Meeting, Ft. Lauderdale, FL 2000.

140. Otitis media and pharyngitis: Current therapeutic concepts, MUSC College of Pharmacy Pediatric continuing education program, Charleston, SC 2000.
141. Current issues in the therapy of Gram-positive infections, MUSC College of Pharmacy Annual Spring Anti-infective Workshop, Charleston, SC 2000
142. Treatment issues in community-acquired pneumonia, University of Houston Infectious Diseases Pharmacotherapy Symposium, Houston, TX 2000.
143. An update on important new antimicrobials in primary care, New Drug Update Program, Medical University of South Carolina Department of Family Medicine, Charleston, SC 2000.
144. Antibiotic Review, Intensive Review of Family Medicine Conference, Medical University of South Carolina Department of Family Medicine, Kiawah Island, SC 2000.
145. Trends in resistance in respiratory pathogens: Implications for empiric therapy, Primary Care 2000, Kiawah Island, SC 2000.
146. Gram-positive resistance: trends and treatment options, Georgia Society of Health-System Pharmacists CE Program, Savannah, GA 2000.
147. ABCs of bacterial resistance workshop, 3<sup>rd</sup> Annual Conference on Infectious Diseases Pharmacotherapy, Orlando, FL 2000.
148. Treatment of resistant Gram-positive bacterial infections, 3<sup>rd</sup> Annual Conference on Infectious Diseases Pharmacotherapy, Orlando, FL 2000.
149. Antibiotic update, South Medical Association Hop Topics in Primary Care, Isle of Palms, SC 2000.
150. Current issues in the treatment of Gram-positive infections, University of Illinois College of Pharmacy Concepts and Controversies in Infectious Diseases Conference, Chicago, IL 2000.
151. Factors in Gram-negative resistance affecting formulary decisions. ASHP Midyear Clinical Meeting, Las Vegas, NV 2000.
152. Bacterial resistance in community-acquired infections, University of Houston Infectious Diseases Pharmacotherapy Symposium, Houston, TX 2001.
153. Interrupting the sepsis cascade: Innovations in biotechnology, University Pharmacotherapy Associates Continuing Education Program, Memphis, TN 2001.
154. Interrupting the sepsis cascade: Innovations in biotechnology, University Pharmacotherapy Associates Continuing Education Program, Charleston, SC 2001.
155. Bacterial resistance in pediatric respiratory tract infections, Pediatric Grand Rounds, Roper Hospital, Charleston, SC 2001.
156. Current issues in the treatment of sepsis, Georgia Society of Health-Systems Pharmacists, Savannah, GA 2001.
157. Viral respiratory illness – Disease overview and patient profile, Costs and complications of viral respiratory illness symposium, Association of Managed Care Pharmacists Annual Meeting, Dallas, TX 2001.
158. Current issues in the treatment of sepsis, Southeastern Pharmaceutical Association, Lumberton, NC 2002.
159. Newer treatment options for otitis media. American College of Clinical Pharmacy Symposium "New Treatment Paradigms with Azalides and Ketolides, ACCP Spring Practice and Research Forum, Savannah, GA 2002.
160. Treatment of Otitis Media in the Pediatric Patient, University of Houston Infectious Diseases Pharmacotherapy Symposium, Houston, TX 2002.

## **TEACHING**

### **COURSES CREATED OR SUBSTANTIALLY REVISED**

<u>Course Title</u>	<u>Credit Hours</u>	<u>University</u>	<u>Program</u>
Instructional Competency	2	Utah	Doctor of Pharmacy
Pathophysiology & Pharmacotherapeutics	4	Utah	Baccalaureate in Pharmacy
Infectious Disease Pharmacotherapeutics	3	Houston	Baccalaureate in Pharmacy
Clinical Pharmacokinetics	4	MUSC	Doctor of Pharmacy
Research Design	3	MUSC	Doctor of Pharmacy

### **CURRENT TEACHING (2001-2002)**

Didactic:

<u>Course</u>	<u>Classroom/Contact Hours</u>
Clinical Pharmacokinetics (PHSCI-676)*	30
Advanced Therapeutics I (PHMPR-705)*12	
Advanced Therapeutics VIII (PHSCI-662)	6
PharmD Conferences	2
Residents' Discussion Series (RITE)	1
Pathophysiology 338 (PA Curriculum)	1.5

\*Course coordinator

Experiential:

<u>Clerkship</u>	<u>Pharm.D. students</u>	<u>Residents</u>
General Pediatrics	4	2
Pediatric Infectious Diseases		2

### **CURRENT UNIVERSITY, PROFESSIONAL AND PUBLIC SERVICE:**

#### **UNIVERSITY SERVICE/COMMITTEES:**

- Member, University Tenure Committee 1993-5
- Member, Health Services Research Committee, 1994-6
- Member, Advisory Committee on Tenure and Promotion, 1995-7
- Member, University Research Council, 1995-8
- Member, Clinical Research Coordinating Committee, 1996-
- Member, Parking Committee, 1996-8
- Member, Healthy South Carolina Grant Review Committee, Spring '97, Fall '97
- Internal Board of Advisors, MUSC Foundation for Research Development Clinical Innovation Group, 1998-
- Member, Dean Evaluation Committee (Dentistry), 1998-9
- Member, MUSC Electronic Research Administration Working Group, 1998-01
- Member, Diversity Advisory Board, College of Health Professions, 1999-
- Member, Faculty Senate, 2000-
  - Member, Faculty Affairs Committee, 2000-1
  - Member, Faculty Contract Committee, 2001-
  - Member, Academic Affairs Committee, 2001-

#### **HOSPITAL COMMITTEES:**

- Member, Antibiotic Subcommittee, 1992-8
- Member, Infection Control Committee, 1995-
- Secretary, Anti-infective Subcommittee, Pharmacy & Therapeutics Committee, 2001-

**COLLEGE OF PHARMACY SERVICE/COMMITTEES:**

Member, Computer Committee, 1992-6  
Member, Research and Graduate Studies Committee, 1992-  
Chair, Research and Graduate Studies Committee, 1996-9  
Member, Ad hoc Committee on Promotion & Tenure Guidelines, 1994-5  
Member, Pharmacoeconomics/Pharmacoepidemiology Faculty Search Committee, 1997-8  
Member, Faculty Affairs Committee, 2000-  
Member, Academic Standing Committee, 2000-1  
Faculty Representative, Academic Council, 2000-  
Chair, Curriculum Committee, 2001-

**COLLEGE OF MEDICINE COMMITTEES:**

Member, Department of Biometry Chair Search Committee, 1997-8  
Member, Clinical Research Task Force, 1998-2001

**PROFESSIONAL & SCIENTIFIC SOCIETIES:**

## American Association of Colleges of Pharmacy

Member, Issues Review Committee, Section of Teachers of Clinical Instruction, 1975-6  
College Delegate to Annual Meeting, 1979, 1985  
Member, Task Force on the PD and Retroactive Pharm.D., Section of Teachers of Clinical Instruction, 1981  
Member, Committee on Alternative Collegiate Administrations, 1982-3  
Member, Program Committee, Section of Teachers of Clinical Instruction, 1983-4  
Chair-elect, Section of Teachers of Pharmacy Practice, 1987-8  
Member, Academic Sections Coordinating Committee, 1987-9  
Chair, Program Committee, Section of Teachers of Pharmacy Practice, 1987-8  
Chair, Section of Teachers of Pharmacy Practice, 1988-9  
Chair, Council of Faculties Committee on Faculty Needs for Entry Level Programs, 1989-91  
Member, Section of Teachers of Pharmacy Practice Planning Commission, 1990-2  
Chair, Section of Teachers of Pharmacy Practice Planning Commission, 1991-2  
Member, Task force on Board Certification Requirements for Pharmacy Practice Faculty, Section of Teachers of Pharmacy Practice, 1995-7  
Member, Research & Graduate Affairs Committee, 1996-7  
Member, Poster & Abstract Review Subcommittee (Program Committee), Section of Teachers of Pharmacy Practice, 1998-9

## American College of Clinical Pharmacy

Chair, Nominations Committee, 1984-5  
Member, Nominations Committee, 1985-6  
Abstract Reviewer for Annual & Winter Forum Meetings, 1987-  
Member, Long Range Planning Committee, 1987-8, 1989-90  
Member, Awards Committee, 1988-9  
Chair, Task Force on the Promotion of Pharmacotherapy Specialization, 1992-3  
Member, Task Force on the Promotion of Pharmacotherapy Specialization, 1993-5  
Member, Program Committee for Annual Meeting (Abstract Review Chair), 1995-6  
Member, Board of Regents, 1997-2000  
Member, Governance Task Force, 1997-2000  
Chair, Infectious Diseases Practice & Research Network, 1998  
Member, Task Force on Leadership, 2000-

## American Society of Health-System Pharmacists

## American Society for Microbiology

## Infectious Diseases Society of America

Society of Infectious Diseases Pharmacists  
Member, Board of Directors, 1990-5  
Chair, Membership Committee, 1991-2  
Chair, Ad Hoc Committee on Subspecialization, 1992-5  
President, 1993-4  
Board Liaison, Election Committee, 1994-5

**EDITORIAL ACTIVITIES:**

**EDITOR:** *The Journal of Infectious Disease Pharmacotherapy* 1993-9

**EDITORIAL BOARDS:**

The Annals of Pharmacotherapy 1977-93  
Antimicrobial Agents and Chemotherapy, 2002-  
Clinical Pharmacy 1981-9  
Pediatric Advisory Committee for Problems in Pediatric Drug Therapy, 3<sup>rd</sup> Ed., 1992  
Pharmacotherapy 1993-  
Journal of Infectious Disease Pharmacotherapy, 2000-  
Journal of Pediatric Pharmacology and Therapeutics, 2000-

**REVIEWER:**

American Journal of Health-System Pharmacy  
American Journal of Pharmaceutical Education  
Annals of Pharmacotherapy  
Antimicrobial Agents and Chemotherapy  
Clinical Pharmacokinetics  
Drugs  
European Journal of Clinical Microbiology and Infectious Diseases  
Guidelines for Administration of Intravenous Medications to Pediatric Patients, 4<sup>th</sup> Ed.,  
monograph reviewer, 1992  
Hospital Formulary  
Managed Care Interface  
Pharmacotherapy

**OTHER PROFESSIONAL SERVICE:**

Member, Board of Directors, American Diabetic Association, Utah Affiliate, 1977-80  
Member, Subcommittee on Infectious Diseases, Clinical Research Committee, National Cystic Fibrosis  
Foundation, 1988-90  
Member, Grant Selection Committee, Astra Clinical Pharmacy Research Award, 1989  
Member, Specialty Council on Pharmacotherapy, Board of Pharmaceutical Specialties, 1992-7  
Vice-Chair, Specialty Council on Pharmacotherapy, Board of Pharmaceutical Specialties, 1992-3  
Chair, Specialty Council on Pharmacotherapy, Board of Pharmaceutical Specialties, 1995-7  
Member, Expert Panel for the Development of Therapeutic Guidelines on Surgical and Nonsurgical  
Prophylaxis, American Society of Health-System Pharmacists, 1995-8.

**PUBLIC SERVICE:**

Co-director of Education, Pharmacist and Counselor, Camp UTADA (Utah Diabetic Association Summer  
Camp for Diabetic Children), 1974-7  
Pharmacist and Counselor, Utah Cystic Fibrosis Summer Camp, 1975-88  
Member, Medical Executive Committee, Mali, West Africa Project (Salt Lake City) 1986-9  
Assistant Den Leader, Cub Scouts of America, Etiwan District, Pack 9, Den 8, 1993-4  
Den Leader, Cub Scouts of America, Etiwan District, South Carolina, Pack 9, Den 8, 1994-5  
Neighborhood Volunteer, March of Dimes, 1998-02